ReviewJournal of clinical medicine2025
SGLT2 Inhibitors and the Risk of Urogenital Infections: A Concise Review.
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Safety Profile of SGLT-2 Inhibitors in Older Adults: A Systematic Review and Network Meta-Analysis.Medical sciences (Basel, Switzerland) · 2026Pooled it
- Dapagliflozin & pioglitazone combination therapy in T2DM with or without MASLD - a systematic review and meta-analysis: PRO-2 study.Frontiers in clinical diabetes and healthcare · 2026Pooled it
- Urogenital Infection Risk Associated With SGLT2 Inhibitors Versus DPP-4 Inhibitors in Type 2 Diabetes and Chronic Kidney Disease: A Nationwide Target Trial Emulation.Clinical pharmacology and therapeutics · 2026Article
- Risk factors for recurrent urinary tract infection after SGLT2 inhibitor reinitiation in type 2 diabetes.Endocrine · 2026Article
- A Patient- and Function-Centric Model/Approach for Hypoglycemia Management in Older Adults.Geriatrics (Basel, Switzerland) · 2026Review
- Article
- Anti-Hyperglycemic Effects of Alpha-Mangostin in Animal Models: A Systematic Review and Meta-Analysis.Life (Basel, Switzerland) · 2026Review
- SGLT2 Inhibitors in Clinical Practice: Cardiorenal Benefits and Risk of Fungal Infections-A Nephrologist's Perspective.Journal of clinical medicine · 2026Review
- Weight change and impact on prognosis in patients with advanced non-small cell lung cancer with concomitant diabetes mellitus treated with sglt2 inhibitors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Review
- Bridging Innovation and Practice in Type 2 Diabetes Mellitus: Novel Antidiabetic Therapies and the Expanding Role of Community Pharmacists.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Efficacy and safety of fixed-dose dapagliflozin-pioglitazone in Indian adults with type 2 diabetes: a phase 3 PRO-1 trial.Diabetology & metabolic syndrome · 2026Article
- Clinical efficacy, safety, and predictors of treatment response to SGLT2 versus DPP-4 inhibitors in type 2 diabetes: a retrospective comparative study.Frontiers in endocrinology · 2026Article
- Sex-specific risk factors for genital infections associated with SGLT2 inhibitors in type 2 diabetes: a retrospective cohort study and disproportionality analysis using JADER.Therapeutic advances in drug safety · 2026Article
- Identification of New Small-Molecule SGLT2 Inhibitors: In-Silico Approach to Therapeutics for Diabetes-Related Complications.ACS omega · 2025Article
- Translating Metabolic Interventions into Breast Cancer Therapy: A Comprehensive Review.Life (Basel, Switzerland) · 2025Review
- SGLT2 Inhibitors in Patients with Urogenital Malformations and Urinary Diversions: Risks, Benefits, and Clinical Considerations.Medicina (Kaunas, Lithuania) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus has become a major public health problem due to aspects such as an alarming increase in prevalence, the morbidity and mortality associated with its complications and, not least, the economic burden. SGLT2 inhibitors are a relatively new but valuable class of drugs that demonstrated multifaceted effects in addition to hypoglycemic action. Moreover, these drugs demonstrated cardiovascular and renal benefits, even in individuals without diabetes, being recommended by current guidelines to patients with a history of cardiovascular disease, or at high risk for it, as well as to patients with chronic kidney disease. The prescription of this class of drugs is limited by the risk of urogenital infections, despite their multiple demonstrated benefits. Data regarding the prevalence of SGLT2 inhibitors associated with urogenital infections depend on several factors related to the study carried out and to other additional conditions that could precipitate such infections. While SGLT2 inhibitors have a well-established association with the risk of genital infections, the association with urinary tract infections remains controversial and uncertain. This review will be focused on urogenital infections associated with the administration of SGLT2 inhibitors, highlighting their prevalence, risk factors, mechanisms involved, clinical relevance and particularities of management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.